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Nonmutagenic Mechanisms in
Carcinogenesis: Role of Protein Kinase C in
Signal Transduction and Growth Control
by I. Bernard Weinstein*
There is accumulating evidence that the multistage carcinogenic process is associated with the pro-
gressive acquisition ofmutations in cellular proto-oncogenes and in growth-suppressor genes. At the same
time, several types of evidence indicate that nongenotoxic agents and epigenetic events also play an
important role in the evolution oftumors. One ofthe most intensively studied nongenotoxic agents is the
phorbol ester tumor promoter 12-0-tetradecanoyl-phorbol-13-acetate (TPA) and related compounds. Since
TPA appears to exert its biologic effects through protein kinase C (PKC), a key enzyme in signal trans-
duction, we have studied this enzyme in considerable detail. Our strategy has been to perturb signal
transduction by developing cell lines that overexpress the I,3 isoform of PKC. Such derivatives of rat
fibroblasts display alterations in morphology and growth factors, altered expression of c-myc, ornithine
decarboxylase, and phorbin, and increased susceptibility to transformation by certain oncogenes, H-ras,
myc, and fos. These findings provide direct genetic evidence that PKC plays acritical role in growth control
and the action of certain growth factors, tumor promoters, and oncogenes. In related studies, we have
characterized the isoform that is overproduced in the above cell systems in terms of its biochemical,
kinetic, and immunologic properties. The enzyme has several properties characteristic of native PKCs. A
surprising finding is that c-H-ras-transformed derivatives of the cells that overexpress PKC,5I display a
several-fold increase in the expression oftheendogenous a, isoform ofPKC and adecrease intheexpression
oftheendogenous e isoform. Thus, cell transformation can lead toalteredexpression ofspecificendogenous
isoforms of PKC.
Colon cancer is the second most common cause of cancer deaths in the U.S., but its precise etiology is
not known. Several types ofevidence will be presented suggestingthat PKC plays arole in the pathogenesis
of this disease. We have also found that bacteria in the human gastrointestinal flora can convert lipids to
diacylglycerol (DAG), a known activator of PKC. We hypothesize that the DAG thus produced influences
the growth of the colonic epithelium and thus plays a tumor-promoting role. The above findings coupled
with findings from other laboratories are discussed in terms of a unifying concept of multistage carcin-
ogenesis, which we have termed "a progressive disorder in signal transduction." This concept emphasizes
the fact that signal transduction pathways are normally linked to each other via complex and overlapping
networks, and the evolution of tumor cells involves both genetic and epigenetic disruptions of such net-
works.
Introduction
Thus far the discussions at this meeting on "Critical
Target Genes in Chemical Carcinogenesis" have dealt
with DNA as the critical target ofchemical carcinogens
and emphasized mutational changes in tumor cells.
Studies in this area have revealed aremarkable number
of changes in the DNA and chromosomes of tumors,
both inexperimental animal and humantumors. Indeed,
there is accumulating evidence that the multistage car-
cinogenic process and the evolution of a fully malignant
tumor involves the progressive acquisition ofboth dom-
inant-acting mutations in cellular proto-oncogenes and
recessive mutations in growth-suppressor genes (1-3).
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Since these data are rather recent and new probes for
cellular proto-oncogenes and suppressorgenes continue
to be developed, I think one can predict that the DNA
of fully malignant tumors often has a large number of
changes in the structure of its DNA.
At the same time, I believe that the above changes
constitute only part ofthe story and that nongenotoxic
agents, acting on cellular targets other than DNA and
through epigenetic mechanisms, also play a major role
in the evolution of tumors and that epigenetic mecha-
nisms also play an important role in the maintenance of
the tumor cell phenotype. There are at least five types
of evidence for this statement. a) The first evidence
comes from studies on the phenomenon of tumor pro-
motion, particularly studies with the phorbol ester tu-
mor promoters (3). b) There is increasing evidence that
a large number of compounds that induce tumors inI. B. WEINSTEIN
rodents do not appear to have genotoxic effects (4).
Although it is possible that further studies will indicate
thatsomeofthese compounds dodamage DNA, perhaps
indirectly through oxidative damage, it is likely that
many of them act through epigenetic mechanisms. c)
The incidence of the major human tumors (other than
lung cancer) in the U. S., i.e., breast, prostate, and
colon cancer, appears to be related to hormonal factors
or dietary lipid, which are nongenotoxic agents (3). d)
There are numerous examples in which the growth and
differentiation of malignant tumor cells can be modu-
lated by nongenotoxic agents, despite the presence of
activated oncogenes and/or chromosomal rearrange-
ments. Thus, the phenotype of the cancer cell is not
fully controlled by its DNA, but is also a function of
epigenetic programs that control gene expression (3).
e) The last type of evidence is more speculative and is
based on the following logic. There is considerable evi-
dencethatthegrowth, development, and differentiation
of normal cells both in the embryo and the adult does
not involve mutational changes in DNA (except in the
immune system). Therefore, epigenetic events play a
profound role in determining the phenotypes ofnormal
cells and can be quite stable at the somatic cell level,
even though the mechanisms are largely unknown [for
review see Holliday (5)]. Sincethe cancercellis agangs-
ter that uses every trick in the book to escape growth
control, it is reasonable to assume that it achieves this
goal by distorting both genetic and epigenetic mecha-
nisms.
As mentioned above, tumor promotion appears to
proceed through epigenetic events, i.e., nonmutational
alterations in gene expression, leading to the selective
outgrowth and phenotypic alteration of initiated cells.
It should also be stressed that DNA-damaging carcin-
ogens can induce not only mutations but also internal
signals (yet to be defined) that apparently enter signal
transduction pathways, thus leading to multiple alter-
ations in gene expression (3,6). This may explain the
fact that some ofthese agents can act as complete car-
cinogens (i.e., both initiators and promoters).
The most detailed information on tumor promotion
comes from studies on the potent phorbol ester tumor
promoter 12-0-tetradecanoyl-phorbol-13-acetate (TPA).
A number of years ago our laboratory and others ob-
tained evidence that TPA is a potent modulator of
growth, differentiation, and gene expression and that
its earliest effects are exerted at the level ofthe plasma
membrane (3). A major advance in our tinderstanding
of mechanisms of tumor promotion came when Nishi-
zuka and colleagues (7) demonstrated that TPAdirectly
activates protein kinase C (PKC), a Ca2+- and phos-
pholipid-dependent protein serine/threonine kinase of
central importance in signal transduction. Subsequent
studies showed that PKC is also the major cellular re-
ceptor for TPA (7). Six separate genes and seven dis-
tinct subspecies ofPKC have been identified, based on
cDNA cloning studies (7-10). The first four subspecies
to be identified (designated a, I, 1I,, and 8 have a
common structure characterizedbyfourconserved (C1-
C4) and five variable (V1-V5) regions. The 5, E, and (
subspecies are related to the first four forms but lack
the C2 conserved region. Thus, like several other com-
ponents ofsignaltransduction pathways, PKC isamult-
igene family. The preservation ofthese multiple forms
in higher organisms during evolution and the fact that
there is differential expression ofthese isoforms in spe-
cific tissues (7-10) suggest that they differwith respect
to their roles in signal transduction, but these differ-
ences remain to be elucidated.
Withthis background inmind, I nowwantto describe
some of our recent studies on PKC because they illus-
trate certain aspects of the complex circuitry involved
in signal transduction and the control of gene expres-
sion.
Effects of Overexpression of PKC
on Growth Control, Oncogene-
Induced Transformation, and Gene
Expression
Ourlaboratory isolated a numberofPKC cDNAs (de-
rived from a rat brain library), including a full-length
clone encodingPKC.1 (8,9). To gain further insight into
the role of PKC in signal transduction and multistage
carcinogenesis, and to better define the biochemical
properties and physiologic effects of a specific isoform
of PKC, we constructed a series of rodent embryo fi-
broblast cell lines that constitutively overproduce high
levels ofthe ,13 isoform ofPKC. We have used a retro-
viral expression vector (pMV7) (11) to transduce the
PKC.1 cDNA into a variety ofcell types; pMV7 lacking
a cDNA insert was used to generate matched control
celllines. R6ratembryofibroblastcellstransducedwith
the pMV7-PKC,1 vector express 20- to 50-fold greater
PKC enzyme activity than control-vector infected cells
and show several disturbances in growth control (9).
These findings, as well as findings we obtained with
derivatives of the murine fibroblast cell line C3H
lOT½/2that also overexpress PKCQ1 (12), provide direct
evidence that this isoform of PKC can alter cell mor-
phology and disturb growth control, particularly in the
presence of TPA.
Although the R6-PKC3 cells are not fully trans-
formed, theydisplay amarked increase in susceptibility
to transformation by an activated c-H-ras oncogene
(13). We previously demonstrated that TPA strongly
enhanced transformation ofthe parental R6 cells by the
sameactivated c-H-ras oncogene (14). Thefindings with
R6-PKC3 cells provide genetic evidence for a cooper-
ative interaction between PKC and a ras oncogene in
the process ofcell transformation. This conclusionis not
confined to fibroblasts since we have found that deriv-
atives of rat liver epithelial cell lines that overexpress
PKC1 (15)alsodisplayincreased susceptibilitytotrans-
formation by the c-H-ras oncogene (L. L. Hsieh and I.
B. Weinstein, unpublished studies).
Our studies with R6-PKC3 cells also indicated that
an appropriate balance between the levels ofPKC and
c-H-ras is required for cell transformation. Thus, TPA
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treatment strongly inhibited ras oncogene-induced
transformation ofR6-PKC3 cells but stimulated ras on-
cogene-induced transformation of control cells. TPA
also inhibited the colony forming ability ofthe c-H-ras
oncogene-transformed R6-PKC3 clones (13). Thus,
overstimulation ofasignaltransductionpathwaylinking
H-ras and PKC can be cytotoxic.
One can rationalize the cooperative interaction be-
tween a ras oncogene and PKC by the fact that ras-
transformed cells often display increased levels of dia-
cylglycerol (DAG) (13). The increased levels of DAG
would provide continuous activation of the high levels
ofPKC,,1 presentinouroverproducercells. Itiscurious,
however, that we have found that the susceptibility of
R6-PKC3 cells to transformation is not confined to ras
oncogenes, since these cells also display increased sus-
ceptibility to transformation by both the v-myc and v-
fos oncogenes (W. -L. W. Hsiao and I. B. Weinstein,
unpublished studies), oncogenes that act downstream
from PKC. The possible significance ofthese findings is
discussed at the end of this paper.
We recently examined the response ofR6-PKC3 cells
tovariousgrowthfactors (S. Hoshinaetal., unpublished
studies). A striking finding was that several agents
when tested alone (i.e., in serum-free medium), includ-
ing epidermal growth factor, platelet-derived growth
factor, TPA, teleocidin, and O-acetylglycerol, produced
a strong stimulation ofDNA synthesis in quiescent R6-
PKC3 cells but had a negligible effect in quiescent R6-
Cl cells, a vector control cell line with normal levels of
PKC. These studies provide genetic evidence that al-
terations in cellular levels of PKC can markedly influ-
encethe response ofcells to specificgrowthfactors. The
underlying mechanisms remain to be determined, but
our findings provide further evidence that PKC plays a
pivotal role in growth control.
We also examined whether cells that overexpress
PKC display alterations in the expression of certain
mitogen-responsive genes (15). Inthese studies weused
derivatives ofthe rat liver epithelial cell lines K16 and
K22 that had been transduced with the vector pMV7-
PKC.1 and express about 10-fold higher PKC activity
than control cells. Despite these high levels of PKC,
these cells did not exhibit gross morphologic changes,
anchorage-independent growth, or tumorigenicity.
When treated with 100 ng/mL ofTPA, the control K16-
MV7 and K22-MV7 cells displayed a slight change in
morphology, whereas the PKC overexpressor cell lines
K16-PKC4 and K22-PKC2 cells displayed a marked
change in morphology. Northern blot analyses demon-
strated that treatment with TPA induced increased le-
vels ofc-fos, c-myc, phorbin, and ODC RNAs in control
K16-MV7 and K22-MV7 cells, with maximum induction
occurring at about 0.5, 1, 8, and 8 hr, respectively. In
K16-PKC4 and K22-PKC2 cells, TPAinduction ofphor-
bin and ODC RNAs was markedly enhanced, but this
was not the case for c-myc and c-fos RNA. In addition,
the levels of c-myc RNA were constitutively higher in
both K16-PKC4 and K22-PKC2 cells than in the control
cells. Taken together, these results provide direct evi-
dence that PKC plays a role in modulating the expres-
sion ofc-myc, phorbin, and ODC RNAs. It seems likely
that PKC also plays a role in the TPA induction of c-
fos, but this was not enhanced in the cells that over-
produce PKC.1, perhaps because the endogenous PKC
is sufficient to saturate this response.
Biochemical and Immunologic
Properties of PKCs in Overproducer
Cells
In addition to mechanistic studies on the role ofPKC
in growth control and transformation, the cell lines we
have developed that overproduce PKC are aconvenient
source for the purification of relatively large amounts
of a specific isoform of the enzyme. This offers a con-
siderable advantage since at the present time it is still
difficult to isolate homogeneous preparations ofspecific
isoforms of PKC from natural sources. An additional
advantage of this approach for studying biochemical
properties of specific PKC isoforms is that the enzyme
is synthesized and posttranslationally modified in the
same cell type in which its biological properties are de-
termined. We have used 10T1/2-PKC4 cells, a deriva-
tive of C3H 1OT1/2 cells that expresses high levels of
PKCO1 (12), for this purpose (16). The PKC,1 purified
from these cells had the following properties: Activity
was dependent on phospholipid and Ca + (optimum 500
,uM), but arachidonic acid could be substituted for the
phospholipid, yieldingaboutone-thirdtheactivity; TPA
or teleocidin stimulated the activity and shifted the
Ca2+ optimum to 10 ,uM; activity was inhibited by H-
7, tamoxifen, and staurosporine (16). In general, these
properties ofPKC,1 are similarto those ofpreparations
of PKC isolated from rat brain.
We have also characterized the PKCs present in our
overproducer cell lines by immunologic methods (C. M.
B. Borner, et al. unpublished studies). Immunocyto-
chemical studies conducted with Susan Jaken indicate
that in the R6-PKC3 cells the overexpressed PKC,1
enzyme is ratherdiffusely distributed in the cytoplasm,
withlittle ornodetectablematerialinthenucleus. After
treatment ofthe cells with phorbol dibutyrate, there is
a dramatic translocation ofthe enzyme tothe periphery
of the cell. Cell fractionation studies also indicate that
phorbol esters induce translocation from the cytosol to
the membrane fraction and downregulation of the
PKC.1 in these cells. Thus, the overexpressed PKC,1
behaves similartothat ofendogenous PKC. Since, how-
ever, the initial level of enzyme is much higher in the
overproducer cells, the biologic responses to TPA are
exaggerated and more prolonged.
Western blot analyses usingisoforn-specific antibod-
ies indicate that the overexpressedPKC,1 has a molec-
ular weight of 78 kDa, which is slightly smaller than
that ofPKC. (80 kDa). We have also characterized the
PKCs present in the H-ras transformed R6-PKC3 and
K16-PKC4 cells. In both cell systems, transformation
wasassociatedwithanincreaseinmembrane-associated
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PKC.1, suggesting that the ras oncogene leads to per-
sistent activation ofthe enzyme. Surprisingly, we found
that the level ofthe endogenous PKCQt isoform was in-
creased about 6- to 10-fold, and the expression of the
endogenous PKCE isoform was decreased several-fold,
inboththe H-ras transformed R6-PKC3 and K16-PKC4
cells. Although it is well established that different iso-
forms ofPKC are expressed in different normal tissues
(7-10), to our knowledge this is the first evidence that
cell transformation can lead to altered expression of
specific endogenous forms of PKC.
In previous studies we have found that the total level
of PKC enzyme activity is usually decreased in human
colon tumors (17), and we are currently examining the
isoform profiles. Increased levels ofspecific isoforms of
PKC are seen during induction of granulocyte differ-
entiation of HL60 cells by vitamin A or dimethylsulf-
oxide (18) and during macrophage differentiation in-
duced by 1,25-dihydroxy D3 (S. Solomon et al., un-
published studies). Increased levels of PKC have also
been seen in some cell lines that display the multidrug
resistance (MDR) phenotype (19,20). It seems likely,
therefore, that the DNA sequences that encode differ-
ent isoforms ofPKC are flanked by different promoter-
enhancer sequences that respond to specific transcrip-
tion factors during the course ofdifferentiation and tu-
mor formation. Differential regulation at the levels of
RNA turnover, translation, and posttranslation could
also play a role in cellular profiles of specific isoforms
of PKC.
Role of PKC in Colon Cancer
Despite the fact that colon cancer is the second most
common cause ofcancer deathsinthe U. S., theetiology
of this disease is not known. Factors that have been
implicated include a high fat and low fiber diet; muta-
gens (i.e., fecapentaene) produced by the intestinal mi-
croflora; bile acids, which inexperimental systems have
a tumor-promoting effect; and genetic predisposition
(21-24). We have obtained the following evidence that
PKC plays a critical role in colon carcinogenesis: a) the
bile acid deoxycholic acid (DOC) stimulates PKC activ-
ity invitro (22), and in intact cells it induces PKC trans-
location and the expression of PKC-responsive genes
(24); b) human colon tumors have decreased levels of
PKC, suggesting downregulation of the enzyme (17);
and c) humancolon tumors display increased expression
of phorbin, a PKC-responsive gene (25).
In recent studies we have examined the hypothesis
that specific bacteria in the intestinal lumen might con-
vert lipids to DAG, which could then enter the colonic
epithelium and activate PKC, thus modulating cell pro-
liferation (26). This would cause a chronic state of in-
creased proliferation of the colonic epithelium, a situ-
ation that is seen in populations at high risk of colon
cancer (21-25).
Indeed, we have found that when bacteria obtained
fromnormalhumanfecesareincubated with 14C-labeled
phosphatidylcholine, there is appreciable production of
DAG. This reaction is strictly dependent on addition of
specific bile acids to the incubation system. Assays of
fecal specimens from 10 normal individuals demon-
strated a 27-fold interindividual variation in the pro-
duction ofDAG in the in vitro assay system and also in
the absolute levels of DAG present in the same fecal
samples. On the other hand, both parameters of DAG
are quite constant in repeated fecal samples obtained
from the same individual.
Other investigators (23) have also found that DAGs
are present in human feces, but they did not identify
their source. Studies are in progress to isolate the spe-
cific intestinal bacteria that produce DAG and to de-
termine whether DAG present in the intestinal lumen
can actually enter colonic epithelial cells, stimulate
PKC, and thereby modulate the growth of these cells.
Should this prove to be the case, then we would have
a mechanism to explain how an interaction between di-
etary lipids, bile acids, and specific bacteria in the in-
testinal lumen could contribute to the risk ofcolon can-
cer in humans.
Holistic View of Signal Transduction
Theabovefindingsindicatethatoverexpression ofthe
I,B isoform ofPKC canproducehighlypleiotropic effects
on cellular morphology, growth, growth control, and
susceptibility to malignant transformation by diverse
types ofoncogenes. Furthermore, some ofthese effects
depend upon the specific cell type in which this enzyme
is expressed and the environment in which the cells are
grown. Studies are in progress to determine whether
other isoforms of PKC produce similar effects.
It is difficult to rationalize the present findings in
terms ofsimple linear pathways ofsignal transduction.
Results obtained with various hormones, neurotrans-
mitters, growth factors, receptors, ion channels, pro-
tein kinases, proteinphosphatases, second messengers,
and transcription factors lead to similar conclusions. It
is apparent, therefore, that the signal transduction
pathways ofmammalian cells constitute a dynamic and
highly interactive network that includes considerable
"cross-talk" and both positive and negative feedback
circuitry. In a sense, all components ofthe system have
the potential ofinfluencing each other. A crude analogy
would be a mechanical clock in which all of the gears
are connected to each other, and a perturbation in one
gear is perceived by the entire system. The complex
maps ofintermediary metabolism in which diverse bio-
chemical pathways can influence each other provide an-
other analogy. This complexity in signal transduction
probably explains why multiple types of exogenous
agents, multiple steps, and multiple mechanisms are
involved in the carcinogenic process and why tumor
phenotypes are highly heterogeneous. It is for these
reasons that I have defined multistage carcinogenesis
as a "progressive disorder in signal transduction."
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